Clinical-stage biopharmaceutical firm Laboratoris Sanifit has enrolled the first patient in CaLIPSO, a Phase IIb study of SNF472 to treat cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients for haemodialysis (HD).

SNF472 is an intravenous drug designed to selectively block the pathological cardiovascular calcification progression, leading to the decrease of cardiovascular events in dialysis patients and in the case of calciphylaxis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CaLIPSO trial is a 52-week, double-blind, randomised, placebo-controlled study that assesses the effects of SNF472 300 and 600mg doses, on the progression of cardiovascular calcification (CVC).

To be conducted at approximately 75 investigation sites in the US, Spain, Italy and the UK, the firm plans to enrol 400 patients in the study.

The results of CaLIPSO trail are expected to be reported in 2019.

"We believe SNF472 has significant potential as a novel treatment of cardiovascular calcification for ESRD patients suffering from this life-threatening clinical condition."

Sanifit chief executive officer Joan Perelló said: "SNF472 selectively blocks the pathological cardiovascular calcification progression and we are delighted to initiate this trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We believe SNF472 has significant potential as a novel treatment of cardiovascular calcification for ESRD patients suffering from this life-threatening clinical condition.

"We have assembled a strong management team and look forward to progressing the development of our lead compound for this high unmet medical need."

The firm has also initiated a Phase II clinical trial to evaluate SNF472 for the treatment of calciphylaxis.

The drug has secured orphan drug designation from the European Medical Agency (EMA) in June 2012 and the US Food and Drug Administration (FDA) in December 2012.